Literature DB >> 21857073

Role of vinpocetine in cerebrovascular diseases.

Sazal Patyar1, Ajay Prakash, Manish Modi, Bikash Medhi.   

Abstract

A cerebrovascular accident, or stroke, is defined as the abrupt onset of a neurological deficit, which can be due to ischemia. Cerebral ischemia is caused by a reduction in blood flow that thereby decreases cerebral metabolism. Chronic cerebral hypoperfusion leads to irreversible brain damage and plays an important role in the development of certain types of dementia. Vinpocetine, chemically known as ethyl apovincaminate, is a vinca alkaloid that exhibits cerebral blood-flow enhancing and neuroprotective effects. Non-clinical and clinical studies have suggested multiple mechanisms responsible for the beneficial neuroprotective effects of vinpocetine. As no significant side effects related to vinpocetine treatment have been reported, it is considered to be safe for long-term use. This vasoactive alkaloid is widely marketed as a supplement for vasodilation and as a nootropic for the improvement of memory. The present review focuses on studies investigating the role of vinpocetine in cerebrovascular diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21857073     DOI: 10.1016/s1734-1140(11)70574-6

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  20 in total

1.  Vinpocetine inhibits Streptococcus pneumoniae-induced upregulation of mucin MUC5AC expression via induction of MKP-1 phosphatase in the pathogenesis of otitis media.

Authors:  Ji-Yun Lee; Kensei Komatsu; Byung-Cheol Lee; Masanori Miyata; Ashley O'Neill Bohn; Haidong Xu; Chen Yan; Jian-Dong Li
Journal:  J Immunol       Date:  2015-05-13       Impact factor: 5.422

2.  Patient-Friendly, Olfactory-Targeted, Stimuli-Responsive Hydrogels for Cerebral Degenerative Disorders Ensured > 400% Brain Targeting Efficiency in Rats.

Authors:  Noha Nafee; Abd El Rahman Ameen; Osama Y Abdallah
Journal:  AAPS PharmSciTech       Date:  2020-11-22       Impact factor: 3.246

Review 3.  An update on vinpocetine: New discoveries and clinical implications.

Authors:  Yi-Shuai Zhang; Jian-Dong Li; Chen Yan
Journal:  Eur J Pharmacol       Date:  2017-11-26       Impact factor: 4.432

4.  Vinpocetine Inhibits NF-κB-Dependent Inflammation in Acute Ischemic Stroke Patients.

Authors:  Fang Zhang; Chen Yan; Changjuan Wei; Yang Yao; Xiaofeng Ma; Zhongying Gong; Shoufeng Liu; Dawei Zang; Jieli Chen; Fu-Dong Shi; Junwei Hao
Journal:  Transl Stroke Res       Date:  2017-07-09       Impact factor: 6.829

5.  Vinpocetine regulates levels of circulating TLRs in Parkinson's disease patients.

Authors:  Zhang Ping; Wu Xiaomu; Xie Xufang; Shao Liang
Journal:  Neurol Sci       Date:  2018-10-12       Impact factor: 3.307

6.  Early alcohol exposure disrupts visual cortex plasticity in mice.

Authors:  Crystal L Lantz; Weili Wang; Alexandre E Medina
Journal:  Int J Dev Neurosci       Date:  2012-05-14       Impact factor: 2.457

Review 7.  Clinical and molecular genetics of the phosphodiesterases (PDEs).

Authors:  Monalisa F Azevedo; Fabio R Faucz; Eirini Bimpaki; Anelia Horvath; Isaac Levy; Rodrigo B de Alexandre; Faiyaz Ahmad; Vincent Manganiello; Constantine A Stratakis
Journal:  Endocr Rev       Date:  2013-12-05       Impact factor: 19.871

8.  Protective effect of vinpocetine against neurotoxicity of manganese in adult male rats.

Authors:  Rania I Nadeem; Hebatalla I Ahmed; Bahia M El-Sayeh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-04-18       Impact factor: 3.000

9.  Vinpocetine Attenuates Pathological Cardiac Remodeling by Inhibiting Cardiac Hypertrophy and Fibrosis.

Authors:  Mei-Ping Wu; Yi-Shuai Zhang; Xiangbin Xu; Qian Zhou; Jian-Dong Li; Chen Yan
Journal:  Cardiovasc Drugs Ther       Date:  2017-04       Impact factor: 3.727

10.  Clinical plasma concentration of vinpocetine does not affect osteogenic differentiation of mesenchymal stem cells.

Authors:  Esma Yıldırım; Gulay Sezer
Journal:  Pharmacol Rep       Date:  2020-08-31       Impact factor: 3.024

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.